No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNYm | 4,969 | 6,494 | 10,136 | 7,851 | 7,311 | 9,008 | N/A | N/A |
| Operating profit | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | CNYm | 612 | 1,072 | 1,813 | 604 | 215 | 479 | N/A | N/A |
| EPS reported | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Established in 1993 and based in Mianyang, China, Lier Chemical Co.,LTD. functions as a comprehensive entity focused on the research, development, manufacturing, and worldwide distribution of agrochemical products. The company's diverse product line encompasses a selection of low-toxicity and low-residue pesticides, including prominent examples such as chloropyridines and organophosphates. Its extensive offerings for crop protection also feature numerous herbicides, specifically pinoxaden, glufosinate-ammonium, diquat, flumioxazin, clodinafop-propargyl, clopyralid acid, picloram, fluroxypyr-meptyl, triclopyr, diuron, bensulfuron-methyl, linuron, pyrazosulfuron-ethyl, nicosulfuron, flufenacet, mefenacet, and quinclorac. Additionally, Lier Chemical provides fungicides like azoxystrobin, epoxiconazole, iprodione, and difenoconazole, alongside insecticides such as chlorpyrifos and pyriproxyfen. Beyond its agricultural chemical focus, the company produces active pharmaceutical ingredients (APIs) and their respective formulations. A substantial part of its business involves the synthesis of a broad spectrum of chemical intermediates, most notably pyridine derivatives including 2-chloropyridine, 2,3-dichloropyridine, 2,5-dichloropyridine, 2,6-dichloropyridine, 2,3,4-trichloropyridine, 2,3,5-trichloropyridine, 2,3,6-trichloropyridine, nitrapyrin, pentafluoropyridine, 2,3,5,6-tetrachloro-4-methylsulfonylpyridine, 6-chloropyridine-2-carbonitrile, 3,6-difluoropyridine-2-carboxylic acid, 2,2'-bipyridine, 2-chloro-4'-fluoroacetophenone, 2-chloro-2',4'-difluoroacetophenone, and 2-fluoro-3-nitrobenzoic acid. Other specialized intermediates manufactured include (E)-4-(dimethylamino)but-2-enoic acid hydrochloride, 4,4'-dichloro-[3,3']bipyridinyl, clopyralid-methyl, methyl 3,4,6-trichloropicolinate, 2,4,5-trichloropyridine, 7-fluoro-6-nitro-4-hydroxyquinazoline, N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine, 4-bromocrotonic acid, 4-N-(3-chloro-4-fluorophenyl)-7-[(3S)-oxolan-3-yl]oxyquinazoline-4,6-diamine, 2-amino-N-(2-chloro-6-methylphenyl)-1,3-thiazole-5-carboxamide, and 5-chloro-8-hydroxyquinoline.
Similar companies
- Hunan Nanling Industrial Explosive Materials Co., Ltd.
- Anhui Wanwei Updated High-Tech Material Industry Co.,Ltd
- Anhui Jinhe Industrial Co.,Ltd.
- Advanced Petrochemical Company
- Shiny Chemical Industrial Co., Ltd.
- National Industrialization Company
- Dawei Technology (Guangdong) Group Co., Ltd.
- Hubei Heyuan Gas Co.,Ltd.
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Lier Chemical Co.,LTD. (002258.SZ)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Established in 1993 and based in Mianyang, China, Lier Chemical Co.,LTD. functions as a comprehensive entity focused on the research, development, manufacturing, and worldwide distribution of agrochemical products. The company's diverse product line encompasses a selection of low-toxicity and low-residue pesticides, including prominent examples such as chloropyridines and organophosphates. Its extensive offerings for crop protection also feature numerous herbicides, specifically pinoxaden, glufosinate-ammonium, diquat, flumioxazin, clodinafop-propargyl, clopyralid acid, picloram, fluroxypyr-meptyl, triclopyr, diuron, bensulfuron-methyl, linuron, pyrazosulfuron-ethyl, nicosulfuron, flufenacet, mefenacet, and quinclorac. Additionally, Lier Chemical provides fungicides like azoxystrobin, epoxiconazole, iprodione, and difenoconazole, alongside insecticides such as chlorpyrifos and pyriproxyfen. Beyond its agricultural chemical focus, the company produces active pharmaceutical ingredients (APIs) and their respective formulations. A substantial part of its business involves the synthesis of a broad spectrum of chemical intermediates, most notably pyridine derivatives including 2-chloropyridine, 2,3-dichloropyridine, 2,5-dichloropyridine, 2,6-dichloropyridine, 2,3,4-trichloropyridine, 2,3,5-trichloropyridine, 2,3,6-trichloropyridine, nitrapyrin, pentafluoropyridine, 2,3,5,6-tetrachloro-4-methylsulfonylpyridine, 6-chloropyridine-2-carbonitrile, 3,6-difluoropyridine-2-carboxylic acid, 2,2'-bipyridine, 2-chloro-4'-fluoroacetophenone, 2-chloro-2',4'-difluoroacetophenone, and 2-fluoro-3-nitrobenzoic acid. Other specialized intermediates manufactured include (E)-4-(dimethylamino)but-2-enoic acid hydrochloride, 4,4'-dichloro-[3,3']bipyridinyl, clopyralid-methyl, methyl 3,4,6-trichloropicolinate, 2,4,5-trichloropyridine, 7-fluoro-6-nitro-4-hydroxyquinazoline, N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine, 4-bromocrotonic acid, 4-N-(3-chloro-4-fluorophenyl)-7-[(3S)-oxolan-3-yl]oxyquinazoline-4,6-diamine, 2-amino-N-(2-chloro-6-methylphenyl)-1,3-thiazole-5-carboxamide, and 5-chloro-8-hydroxyquinoline.
- Hunan Nanling Industrial Explosive Materials Co., Ltd.
- Anhui Wanwei Updated High-Tech Material Industry Co.,Ltd
- Anhui Jinhe Industrial Co.,Ltd.
- Advanced Petrochemical Company
- Shiny Chemical Industrial Co., Ltd.
- National Industrialization Company
- Dawei Technology (Guangdong) Group Co., Ltd.
- Hubei Heyuan Gas Co.,Ltd.
